JP2001501933A - 薬物濫用の治療で使用するハプテン―キャリア結合体およびそれを調製する方法 - Google Patents

薬物濫用の治療で使用するハプテン―キャリア結合体およびそれを調製する方法

Info

Publication number
JP2001501933A
JP2001501933A JP10516754A JP51675498A JP2001501933A JP 2001501933 A JP2001501933 A JP 2001501933A JP 10516754 A JP10516754 A JP 10516754A JP 51675498 A JP51675498 A JP 51675498A JP 2001501933 A JP2001501933 A JP 2001501933A
Authority
JP
Japan
Prior art keywords
carrier
conjugate
hapten
nicotine
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP10516754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001501933A5 (https=
Inventor
エイ． スウエイン，フィリップ
エル． グリーンステイン，ジュリア
エイ． エクセレイ，マーク
エス． フォックス，バーバラ
ピー． パワーズ，スティーブン
エル． ゲフター，マルコルム
Original Assignee
イミュロジック ファーマシューティカル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24894184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2001501933(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イミュロジック ファーマシューティカル コーポレイション filed Critical イミュロジック ファーマシューティカル コーポレイション
Publication of JP2001501933A publication Critical patent/JP2001501933A/ja
Publication of JP2001501933A5 publication Critical patent/JP2001501933A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP10516754A 1996-09-30 1997-09-30 薬物濫用の治療で使用するハプテン―キャリア結合体およびそれを調製する方法 Withdrawn JP2001501933A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/720,487 US5876727A (en) 1995-03-31 1996-09-30 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US08/720,487 1996-09-30
PCT/US1997/017506 WO1998014216A2 (en) 1996-09-30 1997-09-30 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009171424A Division JP2009280599A (ja) 1996-09-30 2009-07-22 薬物濫用の治療で使用するハプテン−キャリア結合体およびそれを調製する方法

Publications (2)

Publication Number Publication Date
JP2001501933A true JP2001501933A (ja) 2001-02-13
JP2001501933A5 JP2001501933A5 (https=) 2006-06-22

Family

ID=24894184

Family Applications (2)

Application Number Title Priority Date Filing Date
JP10516754A Withdrawn JP2001501933A (ja) 1996-09-30 1997-09-30 薬物濫用の治療で使用するハプテン―キャリア結合体およびそれを調製する方法
JP2009171424A Pending JP2009280599A (ja) 1996-09-30 2009-07-22 薬物濫用の治療で使用するハプテン−キャリア結合体およびそれを調製する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009171424A Pending JP2009280599A (ja) 1996-09-30 2009-07-22 薬物濫用の治療で使用するハプテン−キャリア結合体およびそれを調製する方法

Country Status (13)

Country Link
US (1) US5876727A (https=)
EP (2) EP1857121A3 (https=)
JP (2) JP2001501933A (https=)
CN (3) CN1235640C (https=)
AT (1) ATE372786T1 (https=)
AU (1) AU733980B2 (https=)
BR (1) BR9711580A (https=)
CA (2) CA2574049A1 (https=)
DE (1) DE69738140T2 (https=)
DK (1) DK1024834T3 (https=)
ES (1) ES2293664T3 (https=)
PT (1) PT1024834E (https=)
WO (1) WO1998014216A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007521245A (ja) * 2003-11-17 2007-08-02 ノース・キャロライナ・ステイト・ユニヴァーシティ ニコチン誘導体の位置特異的合成
JP2011079849A (ja) * 1998-12-01 2011-04-21 Nabi Biopharmaceuticals ニコチン中毒の治療及び予防のためのハプテン−キャリア複合体
JP2013504618A (ja) * 2009-09-14 2013-02-07 ザ スクリプス リサーチ インスティチュート ニコチンハプテン、免疫抱合体およびその使用
JP2013528616A (ja) * 2010-06-04 2013-07-11 ファイザー バクシーンズ エルエルシー ニコチン中毒の予防または治療用コンジュゲート

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5840307A (en) * 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
AU719289B2 (en) 1995-12-14 2000-05-04 Scripps Research Institute, The Anti-cocaine vaccine
US5817770A (en) 1997-03-21 1998-10-06 Drug Abuse Sciences, Inc. Cocaethylene immunogens and antibodies
JP2001516567A (ja) * 1997-09-19 2001-10-02 セレックス， インコーポレイテッド 抗原の免疫原性および抗体の特異性を改善する方法
SE9801923D0 (sv) * 1998-05-29 1998-05-29 Independent Pharmaceutical Ab Nicotine vaccine
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
GB2361473C (en) * 2000-03-08 2005-06-28 Microgenics Corp Ecstasy-class analogs and use of same in detection of ecstasy-class compounds
GB0031079D0 (en) * 2000-12-20 2001-01-31 Smithkline Beecham Plc Vaccine
WO2002058635A2 (en) * 2001-01-26 2002-08-01 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
NZ511705A (en) * 2001-05-14 2004-03-26 Horticulture & Food Res Inst Methods and rapid immunoassay device for detecting progesterone and other steroids
ES2283589T3 (es) * 2001-06-15 2007-11-01 Vicuron Pharmaceuticals, Inc. Compuestos biciclicos de pirrolidina.
BR0213117A (pt) 2001-10-05 2004-09-21 Cytos Biotechnology Ag Conjugados peptìdeo angiotensina-veìculo e seus usos
US7115266B2 (en) * 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US20050089524A1 (en) * 2002-03-01 2005-04-28 Sanderson Sam D. Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
NZ537003A (en) * 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
US7279340B2 (en) * 2004-04-07 2007-10-09 Dade Behring Inc. Synthesis and application of procainamide analogs for use in an immunoassay
MXPA04006617A (es) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.
US9492400B2 (en) * 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
FR2877668B1 (fr) * 2004-11-10 2007-07-06 Gemac Sa Procede de couplage de molecules non immunogenes, compose intermediaire, produit final obtenu et utilisations
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
ES2776100T3 (es) * 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
WO2007150030A2 (en) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
WO2008147456A2 (en) * 2006-11-20 2008-12-04 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124632A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
EP2630966B1 (en) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
US20110086063A1 (en) * 2008-06-04 2011-04-14 Cornell University Vaccines for prevention and treatment of addiction
US20110182918A1 (en) 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
JP2012519724A (ja) 2009-03-09 2012-08-30 ヘンルイ ウイルリアム シグナルペプチドを担体として有する細菌毒素とのハプテン‐担体抱合体及び免疫原性組成物としてのその使用
KR20120022984A (ko) * 2009-04-21 2012-03-12 셀렉타 바이오사이언시즈, 인크. Ｔｈ１ 편향 반응을 제공하는 면역나노치료법
US20110064750A1 (en) * 2009-07-31 2011-03-17 Nabi Biopharmaceuticals Method and kit for treating nicotine addiction
ES2887335T3 (es) 2010-03-17 2021-12-22 Univ Cornell Vacuna contra las drogas de abuso basada en adenovirus alterado
WO2011123042A1 (en) * 2010-04-01 2011-10-06 Independent Pharmaceutica Ab Vaccination procedure and products for use therein
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
US10004811B2 (en) 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
EP2970319A4 (en) * 2013-03-14 2016-11-09 Alere San Diego Inc 6-ACETYLMORPHINE ANALOGUE AND METHOD FOR THE SYNTHESIS AND USE
US20170107275A1 (en) * 2014-05-19 2017-04-20 The Scripps Research Institute Enantiopure haptens for nicotine vaccine development
CA3041631A1 (en) * 2016-10-24 2018-05-03 The Scripps Research Institute Anti-opioid vaccines
AU2018283973B2 (en) * 2017-06-11 2025-04-24 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
CN108409749B (zh) * 2018-01-30 2019-09-06 中国农业科学院蜜蜂研究所 钩吻素己半抗原和全抗原及其制备方法与应用
WO2020157381A1 (en) * 2019-01-29 2020-08-06 Teknologian Tutkimuskeskus Vtt Oy Methods for screening polypeptides capable of binding specific target molecules and tools related thereto
CN113999163A (zh) * 2021-11-03 2022-02-01 公安部第三研究所 合成大麻素半抗原化合物及其制备方法和用途
CN115974836A (zh) * 2023-01-16 2023-04-18 浙江安诺和生物医药有限公司 一种s-(-)-6-甲基尼古丁水杨酸盐及其制备方法
WO2024238822A1 (en) * 2023-05-17 2024-11-21 Regents Of The University Of Minnesota Heroin vaccine compositions and methods thereof
CN117865868B (zh) * 2023-05-19 2024-09-06 湖南大学 一种功能化分子、其制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05502871A (ja) * 1990-08-22 1993-05-20 サーニー，エリック，ヒューゴ 乱用薬物に対するワクチンおよび免疫血清
WO1993023076A1 (en) * 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
WO1994027576A1 (en) * 1993-05-20 1994-12-08 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375414A (en) * 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US3766162A (en) * 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4045420A (en) * 1973-05-29 1977-08-30 Syva Company Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof
US4053459A (en) * 1975-09-24 1977-10-11 Hoffmann-La Roche Inc. Antibody specific to methaqualone and its metabolites
SU792869A1 (ru) * 1979-03-30 1982-03-30 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений Способ получени конъюгированных антигенов барбитурова кислота-иммуногенный носитель
SU1123704A1 (ru) * 1983-04-08 1984-11-15 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений Способ получени конъюгированных антигенов
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
DE3884731D1 (de) * 1987-10-09 1993-11-11 Ube Industries Monoklonaler Antikörper gegen Methamphetamin, seine Herstellung, Testverfahren und Testsatz für Methamphetamin.
EP0365646B1 (en) * 1988-03-25 1996-05-08 The Rockefeller University Synthetic peptides from streptococcal m protein and vaccines prepared therefrom
EP0363041A1 (en) * 1988-09-21 1990-04-11 Ube Industries, Ltd. Monoclonal antibody to morphine, preparation of monoclonal antibody, assaying kit and assaying method of morphine
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
IL96475A0 (en) * 1989-11-29 1991-08-16 Innovative Tech Center Chimeric proteins
US5256066A (en) * 1991-03-14 1993-10-26 Larussa Joseph Hybridized target acquisition trainer
GB9112553D0 (en) * 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
US5283066A (en) * 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
DK1329226T3 (da) * 1995-03-31 2007-09-24 Xenova Res Ltd Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05502871A (ja) * 1990-08-22 1993-05-20 サーニー，エリック，ヒューゴ 乱用薬物に対するワクチンおよび免疫血清
WO1993023076A1 (en) * 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
WO1994027576A1 (en) * 1993-05-20 1994-12-08 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN4007021906, ＡＬＢＥＲＴ， Ｃ．， ｅｔ ａｌ．, "Ｃｈｒａｃｔｅｒｉｚａｔｉｏｎ ｏｆ ａｎｔｉｂｏｄｉｅｓ ｔｏ ｎｉｔｏｃｉｎｅ．", ＣＨＥＭＩＣＡＬ ＡＢＳＴＲＡＣＴＳ, 1985, Ｖｏｌ．１０３， Ｎｏ．２５, ｐ．２１３０１０ *
JPN4007021907, ＣＡＳＴＲＯ， Ａ．， ｅｔ ａｌ．, "Ｎｉｃｏｔｉｎｅ Ａｎｔｉｂｏｄｉｅｓ： Ｃｏｍｐａｒｉｓｏｎ ｏｆ Ｌｉｇａｎｄ Ｓｐｅｃｉｆｉｃｉｔｉｅｓ ｏｆ Ａｎｔｉｂｏｄｉｅｓ Ｐｒｏｄｕｃｅｄ ａｇａｉｎｓｔ Ｔｗｏ Ｎｉｃｏｔｉｎｅ", Ｅｕｒｏｐｅａｎ Ｊｏｕｒｎａｌ ｏｆ Ｂｉｏｃｈｅｍｉｓｔｒｙ, 1980, Ｖｏｌ．１０４， Ｎｏ．２, ｐ．３３１−３４０ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011079849A (ja) * 1998-12-01 2011-04-21 Nabi Biopharmaceuticals ニコチン中毒の治療及び予防のためのハプテン−キャリア複合体
JP2007521245A (ja) * 2003-11-17 2007-08-02 ノース・キャロライナ・ステイト・ユニヴァーシティ ニコチン誘導体の位置特異的合成
JP2013504618A (ja) * 2009-09-14 2013-02-07 ザ スクリプス リサーチ インスティチュート ニコチンハプテン、免疫抱合体およびその使用
JP2013528616A (ja) * 2010-06-04 2013-07-11 ファイザー バクシーンズ エルエルシー ニコチン中毒の予防または治療用コンジュゲート
JP2015147785A (ja) * 2010-06-04 2015-08-20 ファイザー バクシーンズ エルエルシー ニコチン中毒の予防または治療用コンジュゲート

Also Published As

Publication number Publication date
WO1998014216A2 (en) 1998-04-09
EP1024834B1 (en) 2007-09-12
AU733980B2 (en) 2001-05-31
CN1814301B (zh) 2010-05-26
CN1951502A (zh) 2007-04-25
EP1857121A2 (en) 2007-11-21
ES2293664T3 (es) 2008-03-16
DE69738140D1 (de) 2007-10-25
JP2009280599A (ja) 2009-12-03
CN1814301A (zh) 2006-08-09
WO1998014216A3 (en) 1998-12-10
HK1106140A1 (en) 2008-03-07
AU6483498A (en) 1998-04-24
EP1857121A3 (en) 2011-03-09
EP1024834A2 (en) 2000-08-09
BR9711580A (pt) 2004-03-30
CA2574049A1 (en) 1998-04-09
DE69738140T2 (de) 2008-06-12
US5876727A (en) 1999-03-02
DK1024834T3 (da) 2008-01-21
CN1951502B (zh) 2010-09-15
CN1244130A (zh) 2000-02-09
ATE372786T1 (de) 2007-09-15
HK1027293A1 (en) 2001-01-12
CA2267456A1 (en) 1998-04-09
PT1024834E (pt) 2007-12-18
CN1235640C (zh) 2006-01-11
CA2267456C (en) 2009-03-24

Similar Documents

Publication Publication Date Title
JP2001501933A (ja) 薬物濫用の治療で使用するハプテン―キャリア結合体およびそれを調製する方法
US20100105672A1 (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
WO1998014216A9 (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US20100209449A1 (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
EP0814843B1 (en) Hapten-carrier conjugates for use in drug-abuse therapy
KR100538388B1 (ko) 약물남용 치료시에 사용되는 불완전항원-담체 포합체 및 상기 포합체의 제조방법
AU772309B2 (en) Hapten-carrier conjugates for use in drug-abuse therapy
HK1110794A (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
HK1027293B (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
HK1103035A (en) Hapten-carrier conjugates for use in drug-abuse therapy (cocaine)
HK1103036A (en) Hapten-carrier conjugates for use in drug-abuse therapy
CA2588767A1 (en) Hapten-carrier conjugates for use in drug-abuse therapy

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040929

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20040929

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20040929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080208

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081031

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090916

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091029

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100506

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110111

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110119

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110413